{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T04:30:05Z","timestamp":1684643405479},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41443-019-0180-5","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T23:05:45Z","timestamp":1565910345000},"page":"257-258","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie\u2019s disease"],"prefix":"10.1038","volume":"32","author":[{"given":"Peter","family":"Tsambarlis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"180_CR1","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268\u201374.","journal-title":"J Urol"},{"key":"180_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650\u20136.","journal-title":"BJU Int"},{"key":"180_CR3","doi-asserted-by":"crossref","unstructured":"Tsambarlis PN, Yong R, Levine LA. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie\u2019s disease. Int J Impot Res. 2019;31:15\u20139.","DOI":"10.1038\/s41443-018-0063-1"},{"key":"180_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","volume":"100","author":"J Anaissie","year":"2017","unstructured":"Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG, et al. Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease. Urology. 2017;100:125\u201330.","journal-title":"Urology"},{"key":"180_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie\u2019s disease. J Sex Med. 2016;13:684\u20139.","journal-title":"J Sex Med"},{"key":"180_CR6","doi-asserted-by":"crossref","unstructured":"Kuhlmann PK, DeLay KJ, Anaissie J, Hellstrom WJ, Yafi FA. Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives. Patient Prefer Adherence. 2017;11:431\u201348.","DOI":"10.2147\/PPA.S113507"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41443-019-0180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41443-019-0180-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41443-019-0180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:30:00Z","timestamp":1684618200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-019-0180-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1038\/s41443-019-0180-5","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LAL is a speaker and consultant for Boston Scientific and Coloplast. PT declares that he has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}